Studien
AXI-IIG-02 |
| a phase II / III randomized double-blind study of Sandostatin LAR in combination with Axitinib versus Sandostatin LAR with placebo in patients with advanced G1-G2 neuroendocrinec tumours (WHO2010) of non pancreatic |
|
Ansprechpartner: Prüfer: Dr. Grote Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose |
CPDR001E2201 |
| an open label phase II study to evaluate the efficacy and safety of PDR 001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin who have progressed on prior traetment |
|
Ansprechpartner: Prüfer: PD Dr. A Rinke Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose |
Compete |
| A prospective, randomised, controlled, open label, multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatinreceptor positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) |
|
Ansprechpartner: Prüfer: PD Dr. A. Rinke Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose |
Avenec |
|
Ansprechpartner: Prüfer: PD Dr. A. Rinke Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose |
RamuNET |
|
Ansprechpartner: Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose |
Sonnet |
|
Ansprechpartner: Prüfer: PD Dr. A. Rinke Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose |
Seqtor |
| Randomized phase III openn label cross over study to compare the efficacy and safety of everolimus followed by chemotherapy witz STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNET's |
|
Ansprechpartner: Prüfer: PD Dr. A. Rinke Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose
|
Evinec |
| Zweitlinientherapie bei schlecht differenzierten neuroendokrinen Karzinom/neuroendokrines Karzinom G3 (WHO2010) und neuroendokrinem Tumor G3 - eine "Investigator initiated" Phase II Studie |
|
Ansprechpartner: Prüfer: PD Dr. A. Rinke Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose |
Reminet |
| an european multicenter Phase II / III, randomized double-blind Placebo controlled study evaluating lanreotide as maintenance therapy in patients with non-resectable duodeno-pancreatic neuroendocrine tumours after first line traetment |
|
Ansprechpartner: Prüfer: PD Dr. A. Rinke Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose |
Lebensqualität NET (Patienten unter verschiedenen Therapien) |
|
Ansprechpartner: Prüfer: Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose |